Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
MDM2–p53 inhibition may be effective in glioblastoma (GBM). This study evaluates the pharmacokinetics/pharmacodynamics of BI-907828, a potent antagonist of MDM2, in GBM, and demonstrates a translational paradigm with a focus on a unified “Delivery – Potency – Efficacy” relationship in drug development for central nervous system(CNS) tumors. BI-907828 was tested for cytotoxicity and MDM2–p53 pathway inhibition. Systemic pharmacokinetics and transport mechanisms controlling CNS distribution were evaluated in mice. BI-907828 free fractions in cell media, mouse and human specimens were measured to determine “active” unbound concentrations. Efficacy measures, including overall survival and target expression were assessed in mouse orthotopic GBM xenografts. BI-907828 exhibited potent inhibition of MDM2–p53 pathway and promoted cell death in GBM TP53 wild-type cells. MDM2-amplified cells are highly sensitive to BI-907828, with an effective unbound concentration of 0.1 nmol/L. The CNS distribution of BI-907828 is limited by blood–brain barrier (BBB) efflux mediated by P-gp, resulting in a Kp,uu_brain of 0.002. Despite this seemingly “poor” BBB penetration, weekly administration of 10 mg/kg BI-907828 extended median survival of orthotopic GBM108 xenografts from 28 to 218 days (P < 0.0001). This excellent efficacy can be attributed to high potency, resulting in a limited, yet effective, exposure in the CNS. These studies show that efficacy of BI-907828 in orthotopic models is related to high potency even though its CNS distribution is limited by BBB efflux. Therefore, a comprehensive understanding of all aspects of the “Delivery – Potency – Efficacy” relationship is warranted in drug discovery and development, especially for treatment of CNS tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Multiple MDM2 inhibitors have significant efficacy in GBM preclinical models (7, 8, 10, 11) and have entered early-phase clinical trials in GBM.”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“brigimadlin (10), and navtemadlin (11), and the latter three drugs have reached early-phase clinical trials in GBM (reviewed in ref. 2).”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Blood–brain barrier structure and function and the challenges for CNS drug delivery
Abbott, N. J. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9608-0 · Cited by 909
Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox175 · Cited by 746
Self-citationDrugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
The complexity of p53 stabilization and activation
Lavin, M. F., & Gueven, N. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401925 · Cited by 701
Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., Adkins, C. E., Roberts, A., Thorsheim, H. R., Gaasch, J. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1564 · Cited by 693
On The Rate and Extent of Drug Delivery to the Brain
Hammarlund-Udenaes, M., Fridén, M., Syvänen, S., & Gupta, A. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9502-2 · Cited by 513
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
Research works printed but not linked: 1
- Gollner, 2017 13, Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
Cited by
Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Le, J., Talele, S., Sarkaria, J. N., & Elmquist, W. F. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03574-1 · Cited by 19
“In contrast, BI-907828, another, even more highly potent MDM2 inhibitor, even though with a similarly poor brain penetration (Kp,uu=0.002), demonstrated a profound efficacy in GBM108 PDX orthotopic models [104].”
InfluentialSelf-citationZou, L., Chien, H., Pade, D., Li, Y., Nguyen, M., Bhamidipati, R. K., Wang, Z., Enogieru, O. J., & Wahlstrom, J. L. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01035-8 · Cited by 7
Incorporating Targeted Therapy Into Neuro-Oncology Practice
Geurts, M., Blaquier, J. B., Wijnenga, M. M. J., Kamson, D. O., & de la Fuente, M. I. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473324 · Cited by 7
Zhang, W., Grams, M. P., Oberoi, R. K., Oh, J., Decker, P. A., Sio, T. T.-W., Talele, S., Wilson, Z. C., Connors, M. A., Bakken, K. K., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf093 · Cited by 4
Self-citationGrossman, S. A., Barone, A. K., Strowd, R. E., III, Rais, R., Duke, E., Wearne, E., Price, L., Hendrix, C. W., Schreck, K. C., Lesser, G. J., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag051 · Cited by 4
Self-citation
Metadata
- Authors
- Zhang, W., Vaubel, R. A., Oh, J.-H., Mladek, A. C., Talele, S., Zhang, W., Waller, K. L., Burgenske, D. M., Sarkaria, J. N., & Elmquist, W. F.
- Affiliations
- University of Minnesota (US)
- Mayo Clinic (US)
- Corresponding author
- Sarkaria, Jann N.
- Elmquist, William F.
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2023-10-12
- Volume
- 23
- Issue
- 1
- Pages
- 47-55
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- PMC
- PMC10843165
- OpenAlex
- W4387599152
- Cited by
- 8
- References
- 32
- Citations by year
- 2026: 1 · 2025: 6 · 2023: 1
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U19-CA264362, U01-CA227954)
- National Brain Tumor Society (AWD0006946 / 21-004061)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- BI 907828, MDM2-p53 pathway, glioblastoma, blood-brain barrier penetration, P-glycoprotein efflux, pharmacokinetics, pharmacodynamics, unbound drug concentration, MDM2 amplification, orthotopic xenograft, drug potency, central nervous system tumors
- MeSH terms
- Animals, Blood-Brain Barrier, Brain Neoplasms, Glioblastoma, Heterocyclic Compounds, 4 or More Rings, Humans, Spiro Compounds, Tumor Suppressor Protein p53, Cell Line, Tumor, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma. https://app.cochat.ai/papers/10.1158/1535-7163.mct-23-0217
- The paper
- Zhang, W., Vaubel, R. A., Oh, J.-H., Mladek, A. C., Talele, S., Zhang, W., Waller, K. L., Burgenske, D. M., Sarkaria, J. N., & Elmquist, W. F. (2024). Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-23-0217
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.